NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease

Journal of Neuroscience Research

Volumn 87, Issue 10, 2009, Pages 2308-2318

  Bustos, Gonzalo ^a   Abarca, Jorge ^a   Bustos, Victor ^a   Riquelme, Eduardo ^a   Noriega, Viviana ^a   Moya, Catherine ^a   Campusano, Jorge ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

6 OHDA; BDNF; NMDA receptors; Presymptomatic Parkinson's disease; Substantia nigra

Indexed keywords

ASPARTIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; DIZOCILPINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; DOPAMINE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; GENE EXPRESSION REGULATION; MALE; MESENCEPHALON; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UPREGULATION; ANALYSIS OF VARIANCE; ANIMAL; CELL COUNT; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; GENETICS; HEMISPHERIC DOMINANCE; METABOLISM; METHODOLOGY; MICRODIALYSIS; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANALYSIS OF VARIANCE; ANIMALS; ASPARTIC ACID; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL COUNT; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; FUNCTIONAL LATERALITY; GLUTAMIC ACID; MALE; MICRODIALYSIS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; UP-REGULATION;

EID: 69249213726     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22063     Document Type: Article

References (53)

1. Abarca J, Gysling K, Roth RH, Bustos G. 1995. Changes in extracellular levels of glutamate and aspartate in rat substantia nigra induced by dopamine receptor ligands: in vivo microdialysis studies. Neurochem Res 20:159-169.
2. Abarca J, Bustos G. 1999. Differential regulation of glutamate, aspartate and gamma-amino-butyrate release by N-methyl-D-aspartate receptors in rat striatum after partial and extensive lesions of the nigro-striatal dopamine pathway. Neurochem Int 35:19-23.
3. Acheson AL, Zigmond MJ, Stricker EM. 1980. Compensatory increase in tyrosine hydroxylase activity in rat brain after intraventricular injections of 6-hydroxydopamine. Science 207:537-540.
4. Agid Y, Javoy F, Glowinski J. 1973. Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigro-striatal dopaminergic system in the rat. Nat New Biol 245:150-151.
5. Aliaga E, Rage F, Bustos G, Tapia-Arancibia L. 1998. BDNF gene transcripts in mesencephalic neurons and its differential regulation by NMDA. NeuroReport 9:1959-1962.
6. Aliaga E, Rage F, Tapia-Arancibia L, Bustos G. 1999. Negative regulation of brain-derived neurotrophic factor mRNA expression by kainic acid in substantia nigra. Mol Brain Res 71:341-344.
7. Aliaga E, Cárcamo C, Abarca J, Tapia-Arancibia L, Bustos G. 2000. Transient increase of brain derived neurotrophic factor mRNA expression in substantia nigra reticulata after partial lesion of the nigrostriatal dopaminergic pathway. Mol Brain Res 79:150-155.
8. Altar CA, Marien MR. 1989. Preservation of dopamine release in the denervated striatum. Neurosci Lett 96:329-334.
9. Andres ME, Gysling K, Bustos G. 1998. Differential regulation of dopamine release by N-methyl-D-aspartate receptors in rat striatum after partial and extreme lesions of the nigro striatal pathway. Brain Res 797:255-266.
10. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. 1973. Brain dopamine and the syndromes of Parkinson and Hungtington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455.
11. Bezard E, Gross CE. 1998. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog. Neurobiology 55:93-116.
12. Bezard E, Boraud T, Bioulac C, Gross CE. 1997a. Compensatory effects of glutamatergic inputs to the substantia pars compacta in experimental parkinsonism. Neuroscience 81:399-404.
13. Bezard E, Boraud T, Bioulac C. 1997b. Presymptomatic revelation of experimental parkinsonism. NeuroReport 8:435-438.
14. Bezard E, Boraud T, Bioulac C. 1999. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanism. Eur J Neurosci 11:2167-2170.
15. Bezard E, Doero S, Prunier C, Ravenscroff P, Chaĺn S, Guilloteau D, Crossman AR, Bioulac C, Brotchie JM, Gross CE. 2001. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- lesioned macaque model of Parkinson's disease. J Neurosci 21:6853-6861.
16. Bezard E, Gross CE, Brotchie JM. 2003. Presyntomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 26:215-221.
17. Bishop JF, Mueller GP, Morradian MM. 1994. Alternate 5′ exons in the rat brain-derived neurotrophic factor gene: differential patterns of expression across brain regions. Mol Brain Res 26:225-232.
18. Breysse N, Amahic M, Salin P. 2003. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizinag activity of selective basal-ganglia structures in parkinsonian ratas. J Neurosci 23: 8302-8309.
19. Bustos G, Abarca J, Campusano J, Bustos V, Noriega V, Aliaga E. 2004. Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-derived neurotrophic factor expression in mesencephalic structures of the brain. Brain Res Rev 47: 126-144.
20. Bustos G, Abarca J, Bustos V, Riquelme E, Noriega V, Campusano J, Moya C. 2006. The glutamate connection, the BDNF/trkB receptor complex, and their role during adaptive and plastic responses in substantia nigra in a rat model of presymptomatic Parkinson's disease. FENS Forum Abstracts, vol. 3, A200.7.
21. 2+-responsive transcription in neurons. J Neurosci 23:2572-2581.
22. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
23. Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39:889-909.
24. Hardingham GE, Fukunaga Y, Bading H. 2002. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5:405-414.
25. Hefti F, Enz E, Melaned E. 1985. Partial lesions of the nigro striatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurons by drugs. Neuropharmacology 24:19-23.
26. Ichitani Y, Okamura H, Nakahara D, Nagatsu I, Ibata Y. 1994. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra. Exp Neurol 130:269-278.
27. Kirik D, Rosenblad D, Björklund A. 1998. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxy-dopamine in the rat. Exp Neurol 152:259-277.
28. Kish SJ, Shannak K, Hornykiewicz O. 1988. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 318:876-880.
29. Kokaia Z, Metsis M, Kokaia M, Bengzon J, Elmer E, Smith ML, Timmusk T, Siesjo BK, Persson H, Lindvall O. 1994. Brain insults in rats induce increased expression of the BDNF gene through differential use of multiple promoters. Eur J Neurosci 6:587-596.
30. Lang AE, Obeso JA. 2004. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system in not enough. Lancet Neurol 3:309-316.
31. Leon-Perez CL. 2006. Efecto de K252A, antagonista del receptor del factor neurotrófico derivado de cerebro (BDNF), sobre la liberación de glutamato, aspartato, ácido gama aminobutírico y dopamina, en cuerpo estriado y substantia nigra de rata: estudios in vivo mediante la técnica de microdíalisis. Memoria de investigación para optar al título de Bioquímico, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
32. MacDermott AB, Mayer ML, Westbrook GL, Smith SJ, Barker JL. 1986. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurons. Nature 321:519-522.
33. Marin C, Rodriguez-Oroz MC, Obeso JA. 2006. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: Have we wasted our time? Exp Neurol 197:269-274.
34. 18F] dopa-PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 59: 597-600.
35. Nakayama M, Gahara Y, Kitamura T, Ohara O. 1994. Distinctive four promoters collectively direct expression of brain-derived neurotrophic factor gene. Mol Brain Res 21:206-218.
36. Obeso JA, Rodriguez-Oroz MC, Lanciego JL, Rodriguez Díaz M. 2004. How does Parkinson's disease begin? Trends Neurosci 27:125-127.
37. Oveslati A, Breysse N, Amabric M, Kerkerian-Le Goff L, Salin P. 2005. Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism. Eur J Neurosci 22:2765-2774.
38. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates. Academic Press, New York.
39. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Tagasaki DM. 1995. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxy-dopamine. Neuroscience 67:63-647.
40. Sauer H, Oertel WH. 1994. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immuno-cytochemical study in the rat. Neuroscience 59:401-415.
41. Shimohama S, Sawada H, Kitamura Y, Taniguchi T. 2003. Disease model: Parkinson's disease. Trends Mol Med 9:360-365.
42. Skaper SD, Negro A, Facci L, Dal Toso R. 1993. Brain-derived neurotrophic factor selectively rescues mesencephalic dopaminergic neurons from 2,4,5-trihydroxyphenylalanine-induced injury. J Neurosci Res 34:478-487.
43. Spina MB, Squinto SP, Millar J, Lindsay RM, Hyman C. 1992. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 59:99-106.
44. 2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20:709-726.
45. Tao X, West AE, Chen WG, Confar G, Greenberg ME. 2002. A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF. Neuron 33:383-395.
46. Teng HK, Teng KK, Lee R, Wright S, Tevar S, Almeida RD, Kermani P, Torkin R, Chen Z-Y, Lee FS, Kraemer RT, Nykjaer A, Hempstead BL. 2005. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75 and Sortilin. J Neurosci 25:5455-5463.
47. Timmusk T, Palm K, Matsis M, Reintam T, Paalme V, Saama M, Persson H. 1993. Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron 10:475-489.
48. Ungerstedt U. 1968. 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107-110.
49. Vanhoutte P, Bading H. 2003. Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation. Curr Opin Neurobiol 13:366-371.
50. Vila M, Perier C, Feber J, Yolnik J, Faucheasux B, Ruberg M, Raisman-Vogari R, Agid Y, Hirsch EC. 2000. Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements. Eur J Neurosci 12:337-344.
51. Zigmond MJ. 1997. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism. Neurobiol Dis 4:247-253.
52. Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM. 1984. Neurochemical compensation after nigrostriatal bundle-injury in an animal model of preclinical parkinsonism. Arch Neurol 41:856-861.
53. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. 1990. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13:290-296.